Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 30, 2008 Brian Lawler	No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug.
The Motley Fool February 25, 2008 Brian Lawler	The Most Interesting FDA Review for 2008 Eli Lilly preps for an upcoming FDA review of its top pipeline drug, the blood thinner prasugrel.
The Motley Fool December 31, 2008 Brian Orelli	An Imminent Drug Approval? Really? Lilly may finally hear about prasugrel.
The Motley Fool November 16, 2009 Brian Orelli	Music to Health-Care Investors' Ears Are faster FDA review times coming?
The Motley Fool January 5, 2010 Brian Orelli	Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix.
The Motley Fool December 19, 2008 Brian Orelli	Eli Lilly's Good News Misses the Mark EU approval of its blood thinner is nice, but U.S. approval is what will really matter.
The Motley Fool October 23, 2009 Brian Orelli	I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
The Motley Fool August 31, 2009 Brian Orelli	Thinning Out Plavix's Monopoly Until now sanofi-aventis' and Bristol-Myers Squibb's Plavix didn't have a monopoly on the blood-thinning market, but it was pretty darn close. But now, another competitor's on the way.
The Motley Fool June 25, 2008 Brian Lawler	Why the Lilly Delay, FDA? A government review of the company's top drug candidate gets pushed back.
The Motley Fool July 29, 2010 Brian Orelli	This FDA Panel Isn't Brilliant Why does AstraZeneca's blood thinner Brilinta work better outside the U.S. than here at home? The Food and Drug Administration's advisory panel didn't seem to have a good explanation, but they didn't appear to care much, either.
The Motley Fool July 27, 2010 Brian Orelli	Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool October 30, 2009 Brian Orelli	Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool January 28, 2011 Brian Orelli	Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
The Motley Fool September 4, 2008 Brian Lawler	Sitting Tight in September This month, several drugmakers will hear about compounds awaiting approval, so we can expect some volatility in their share prices. Read on to see who's awaiting FDA news.
The Motley Fool March 15, 2010 Brian Orelli	Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison.
The Motley Fool June 26, 2009 Brian Orelli	Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market.
The Motley Fool December 28, 2010 Brian Orelli	Double-Digit Increase! Haven't We Learned Anything? MannKind's investors need a history lesson.
The Motley Fool September 29, 2011 Brian Orelli	Investors Guide to the New PDUFA Changes are in the air for drugmakers and the FDA.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
The Motley Fool December 9, 2008 Brian Orelli	The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool February 27, 2009 Brian Orelli	Get a Life, Congress! A Congressional investigation into whether the FDA was right to pull a doctor off of the advisory panel for Eli Lilly's blood thinner prasugrel illustrates why Congress needs to keep its nose out of scientific discussions.
The Motley Fool April 13, 2009 Brian Orelli	Will These Drugs Get Past the FDA? Hopefully April won't bring showers of tears to these drugmakers: Eli Lilly... AstraZeneca... Bristol-Myers Squibb... Novo Nordisk... Johnson & Johnson...
The Motley Fool February 12, 2009 Brian Orelli	Patent Cliff? Bring It On Sanofi-aventis isn't interested in doing a large deal.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool December 1, 2008 Brian Orelli	It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies.
The Motley Fool January 13, 2011 Brian Orelli	FDA Panel Gives Eli Lilly Indigestion Eli Lilly's new acquisition causes a tummy ache.
The Motley Fool June 30, 2010 Brian Orelli	When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions.
The Motley Fool January 26, 2009 Brian Orelli	Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues.
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool February 4, 2009 Brian Orelli	Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
The Motley Fool October 24, 2008 Brian Orelli	Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
The Motley Fool December 23, 2009 Brian Orelli	2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool March 5, 2010 Brian Orelli	How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot.
The Motley Fool August 20, 2010 Brian Orelli	Depression Is Painful. Advisory Panels More So. Eli Lilly's Cymbalta has a rough time in from of the panel of experts.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
The Motley Fool April 7, 2009 Brian Orelli	Bristol-Myers Squibb: On the Patent Cliff's Edge Bristol-Myers Squibb changed its huge patent cliff into two smaller falls with a larger ledge in the middle.